475,750 Shares in Pharvaris N.V. $PHVS Acquired by Elmind Capital LP

Elmind Capital LP acquired a new position in shares of Pharvaris N.V. (NASDAQ:PHVS) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 475,750 shares of the company’s stock, valued at approximately $13,202,000. Pharvaris makes up about 3.9% of Elmind Capital LP’s portfolio, making the stock its 10th largest position.

Several other hedge funds have also modified their holdings of the company. California State Teachers Retirement System raised its holdings in shares of Pharvaris by 2.2% during the 4th quarter. California State Teachers Retirement System now owns 23,982 shares of the company’s stock worth $666,000 after acquiring an additional 520 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Pharvaris by 30.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after acquiring an additional 783 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in shares of Pharvaris during the 4th quarter worth approximately $35,000. Public Employees Retirement System of Ohio raised its holdings in shares of Pharvaris by 20.7% during the 4th quarter. Public Employees Retirement System of Ohio now owns 7,569 shares of the company’s stock worth $210,000 after acquiring an additional 1,300 shares in the last quarter. Finally, Legal & General Group Plc raised its holdings in shares of Pharvaris by 17.2% during the 2nd quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock worth $203,000 after acquiring an additional 1,695 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on PHVS. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a report on Tuesday, April 21st. Citizens Jmp decreased their price objective on Pharvaris from $75.00 to $74.00 and set a “market outperform” rating on the stock in a report on Wednesday, May 13th. Wedbush upped their price objective on Pharvaris from $41.00 to $42.00 and gave the stock an “outperform” rating in a report on Tuesday, April 7th. HC Wainwright reaffirmed a “buy” rating on shares of Pharvaris in a report on Tuesday. Finally, Wall Street Zen raised Pharvaris from a “sell” rating to a “hold” rating in a report on Saturday, June 6th. Ten analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $49.18.

Pharvaris Stock Performance

NASDAQ PHVS opened at $33.41 on Thursday. The company has a market cap of $2.19 billion, a P/E ratio of -10.51 and a beta of -2.35. The business’s 50 day moving average price is $29.81 and its 200-day moving average price is $27.67. Pharvaris N.V. has a fifty-two week low of $16.00 and a fifty-two week high of $33.50.

Pharvaris (NASDAQ:PHVS) last released its earnings results on Tuesday, May 12th. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.82) by $0.12. As a group, equities analysts predict that Pharvaris N.V. will post -3.22 EPS for the current year.

Insider Activity

In other news, Director Robert Glassman sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $29.82, for a total transaction of $298,200.00. Following the transaction, the director owned 10,500 shares of the company’s stock, valued at approximately $313,110. The trade was a 48.78% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Berndt Modig sold 23,333 shares of the business’s stock in a transaction that occurred on Thursday, April 9th. The shares were sold at an average price of $27.74, for a total value of $647,257.42. Following the transaction, the chief executive officer directly owned 142,084 shares in the company, valued at approximately $3,941,410.16. This represents a 14.11% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 214,909 shares of company stock worth $6,421,745. Company insiders own 11.84% of the company’s stock.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.